What is Moximed?
Headquartered in Fremont, California, Moximed specializes in the design and manufacturing of innovative surgical equipment specifically engineered to address the debilitating effects of osteoarthritis. By focusing on joint-preserving interventions, the company occupies a critical niche in the orthopedic market, offering alternatives to traditional total joint replacement surgeries. Moximed's growth trajectory has been marked by a series of strategic funding milestones, evolving from early-stage development to its current position as a mature player in the medical device landscape. The company's commitment to improving patient mobility through biomechanical innovation has solidified its reputation among both clinical practitioners and healthcare investors.
How much funding has Moximed raised?
Moximed has raised a total of $239.8M across 6 funding rounds:
Private Equity
$10M
Series A
$45.8M
Series B
$33M
Series C
$50M
Series C
$40M
Series D
$61M
Private Equity (2009): $10M, investors not publicly disclosed
Series A (2011): $45.8M led by Gilde Healthcare, Frazier Healthcare Partners, and GBS Venture Partners
Series B (2015): $33M supported by New Enterprise Associates, Morgenthaler Private Equity, Gilde Healthcare, GBS Venture Partners, and Vertex Holdings
Series C (2017): $50M featuring Morgenthaler Private Equity, Gilde Healthcare, Vertex Healthcare, NEA, GBS Venture Partners, and Advent Venture Partners
Series C (2022): $40M backed by GBS Venture Partners, Future Fund, Advent Life Sciences, New Enterprise Associates, Vertex Healthcare, and Gilde Healthcare
Series D (2024): $61M with participation from Elevage Medical Technologies, Gilde Healthcare, and New Enterprise Associates
Key Investors in Moximed
Gilde Healthcare
A specialized healthcare investment firm managing over 1.4 billion euros across venture and growth strategies, focusing on businesses that enable better care at lower costs.
New Enterprise Associates
A prominent venture capital firm established in 1977, dedicated to partnering with entrepreneurs to build transformative businesses across the technology and healthcare sectors.
GBS Venture Partners
A venture capital firm focused on investing in innovative healthcare companies, supporting the development of groundbreaking medical solutions and pharmaceuticals.
What's next for Moximed?
With the successful closure of its most recent funding round, Moximed is well-positioned to accelerate its commercialization efforts and expand its clinical footprint. The infusion of capital will likely be directed toward scaling manufacturing capabilities, advancing ongoing clinical trials, and broadening market access for its flagship surgical systems. As the company transitions into this next phase of growth, the focus remains on establishing its technology as a standard of care for patients seeking to delay or avoid invasive joint replacement procedures. The continued support from its long-term investor syndicate provides the necessary operational stability to navigate the complex regulatory and competitive landscape of the global orthopedic market.
See full Moximed company page
